{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-23-007072","form_type":"8-K","ticker":"PGEN","cik":"0001356090","company_name":"PRECIGEN, INC.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.546524+00:00","generated_at":"2026-06-15T06:04:44.471141+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Precigen Q1 loss narrows to $22.7M; raises $72.8M in offering; pipeline advances","bullets":["Revenue fell 66% YoY; Q1 operating loss $22.7M ($0.10 EPS) vs $23.9M ($0.12 EPS) in Q1 2022.","Cash, equivalents and investments $125.4M; net proceeds of $72.8M from public offering at $1.75/share.","Retired $29.5M of convertible notes; remaining $13.8M due July 2023 to be retired with restricted cash.","Phase 1 PRGN-2012 data: 50% complete response; Phase 2 enrollment completed (N=23).","First patient dosed with PRGN-3007 UltraCAR-T (PD-1 checkpoint); regained exclusive rights to CD19 and BCMA targets."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-23-007072","json":"https://secwatch.observer/filing/0000950103-23-007072.json","markdown":"https://secwatch.observer/filing/0000950103-23-007072.md","text":"https://secwatch.observer/filing/0000950103-23-007072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356090/000095010323007072/0000950103-23-007072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356090/000095010323007072/dp193579_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T06:04:44.471141+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"59f1d8f7a718f6e2860c1be83909930788e85695","claim":"PRECIGEN, INC. reported financial results for the quarter ended March 31, 2023.","evidence_excerpt":"Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated May 10, 2023, reporting its financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1356090/000095010323007072/0000950103-23-007072-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}